Doctor-prescribed peptides, shipped to your door.

Current Ozempic injection safety guide

Ozempic injection side effects: current label rates and warning signs

Review common Ozempic injection side effects, product-specific trial rates, serious warning signs, glucose and hydration questions, and compounded-semaglutide distinctions.

Educational guideUpdated August 7, 2026

A label-first Ozempic injection side-effect check

1

Confirm the exact product and route: FDA-approved Ozempic injection, Ozempic tablets, another branded semaglutide product, or a patient-specific compounded preparation.

2

Describe each symptom, when it began, severity, recurrence, food and fluid intake, urine output, glucose readings when relevant, and any refill or clinician-directed treatment change.

3

Separate common digestive symptoms from severe abdominal pain, dehydration, low blood sugar, vision, gallbladder, allergy, procedure, or thyroid warning signs.

4

Share insulin, sulfonylureas, other diabetes medicines, kidney or eye history, severe stomach-emptying problems, pregnancy plans, procedures, and the complete medication list.

5

Contact the responsible prescriber before skipping, repeating, stopping, restarting, or changing treatment; use urgent care for serious warning signs.

Direct answer

The most common adverse reactions in current Ozempic injection labeling are nausea, vomiting, diarrhea, abdominal pain, and constipation. In two placebo-controlled type 2 diabetes trials, nausea occurred in 15.8% and 20.3% of participants receiving Ozempic 0.5 mg and 1 mg, respectively, versus 6.1% with placebo. These are product-, dose-, and study-specific rates—not a prediction for one patient, Ozempic tablets, Wegovy, or compounded semaglutide. Contact the prescriber for persistent, worsening, recurrent, or treatment-limiting symptoms and before changing treatment. Severe or persistent abdominal pain, repeated vomiting or inability to keep fluids down, markedly reduced urination, fainting or confusion, jaundice, sudden vision change, facial or throat swelling, trouble breathing, or a neck mass with swallowing difficulty needs prompt in-person or emergency assessment.

Common adverse reactions

Current Ozempic injection trials report five common digestive reactions

The June 2026 Novo Nordisk Ozempic injection label reports adverse reactions from two placebo-controlled trials in adults with type 2 diabetes. Nausea occurred in 6.1% with placebo, 15.8% with Ozempic 0.5 mg, and 20.3% with Ozempic 1 mg. The corresponding rates were 2.3%, 5%, and 9.2% for vomiting; 1.9%, 8.5%, and 8.8% for diarrhea; 4.6%, 7.3%, and 5.7% for abdominal pain; and 1.5%, 5%, and 3.1% for constipation. These comparisons describe studied groups and do not prove the cause, severity, or expected duration of one person’s symptom.

  • Keep each percentage tied to the labeled 0.5 mg or 1 mg Ozempic injection trial group; the table does not provide a 2 mg rate for these reactions.
  • Do not add the dose-group percentages together, compare them as though the trials were head-to-head effectiveness studies, or transfer them to another product or route.
  • Report symptoms that are persistent, recurrent, worsening, severe, intake-limiting, or disruptive even when they appear on a common-reaction list.

Digestive effects and hydration

Overall stomach symptoms and treatment discontinuation were also dose-group specific

Across the placebo-controlled trial pool, gastrointestinal adverse reactions occurred in 15.3% of participants receiving placebo, 32.7% receiving Ozempic 0.5 mg, and 36.4% receiving Ozempic 1 mg. The label says most nausea, vomiting, and diarrhea reports occurred during dose escalation. Gastrointestinal reactions led to discontinuation in 0.4% of placebo participants, 3.1% receiving 0.5 mg, and 3.8% receiving 1 mg. Those observations do not create a universal adjustment period or tell a patient to continue through severe symptoms.

  • Record vomiting or diarrhea episodes, the ability to keep fluids and food down, urine amount and color, dizziness, fainting, weakness, and recent illness or heat exposure.
  • Current labeling warns about acute kidney injury due to volume depletion and says kidney function should be monitored when adverse reactions could cause dehydration.
  • Severe or persistent abdominal pain, repeated vomiting, inability to keep fluids down, markedly reduced urination, fainting, confusion, jaundice, or abdominal swelling needs prompt assessment.

Serious label warnings

Common stomach symptoms should not obscure pancreatitis, gallbladder, eye, allergy, or thyroid warning signs

The current Ozempic injection label includes a boxed warning about thyroid C-cell tumors observed in rodents; it is unknown whether Ozempic causes these tumors in humans. Ozempic is contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2. The label also addresses acute pancreatitis, diabetic-retinopathy complications, serious hypersensitivity, acute gallbladder disease, severe gastrointestinal reactions, kidney injury from volume depletion, and pulmonary aspiration during anesthesia or deep sedation. A page cannot diagnose these conditions or replace an examination.

  • Seek prompt care for severe or persistent abdominal pain, especially pain that may spread to the back, with or without nausea or vomiting; jaundice, fever, or right-upper-abdominal pain also needs assessment.
  • Report sudden or worsening vision symptoms promptly, especially with a history of diabetic retinopathy or a substantial change in glucose control.
  • Trouble breathing or swallowing, facial or throat swelling, fainting, widespread hives, a neck mass, persistent hoarseness, or rapidly developing serious symptoms requires urgent or emergency evaluation.

Glucose, procedures, and medical history

Other medicines and conditions can change the side-effect review

Ozempic injection is labeled for adults with type 2 diabetes, including specified cardiovascular and chronic-kidney-disease risk-reduction uses. Low-blood-sugar risk can increase when it is used with insulin or an insulin secretagogue such as a sulfonylurea. The label says Ozempic is not recommended in patients with severe gastroparesis and instructs patients to tell clinicians about planned surgery or procedures because GLP-1 receptor agonists have been associated with rare pulmonary-aspiration reports during general anesthesia or deep sedation. Treatment and peri-procedure decisions should be individualized by the responsible clinical team.

  • Share insulin, sulfonylureas, metformin, SGLT2 inhibitors, diuretics, blood-pressure medicines, eye history, kidney history, gallbladder history, stomach-emptying symptoms, pregnancy plans, and upcoming procedures.
  • If glucose monitoring is part of care, record readings with symptoms, meals, activity, alcohol, and diabetes medicines and follow the individualized low-blood-sugar plan.
  • Do not improvise a dose hold, catch-up dose, restart, anti-nausea medicine, laxative, hydration recipe, or procedure plan from generic online advice.

Route and product identity

Ozempic injection rates do not automatically apply to tablets or compounded semaglutide

Current official records include a Novo Nordisk Ozempic injection label and a separate combined Ozempic and Rybelsus tablet label set. The injection trial rates on this page belong to the manufacturer injection label. A patient-specific compounded semaglutide preparation is not FDA-approved Ozempic or a generic Ozempic finished product and may differ in concentration, inactive ingredients, presentation, container, supplies, storage, and beyond-use date. Confirm the exact label before interpreting a symptom or deciding what should happen next.

  • Preserve the product name, route, prescription and pharmacy label, strength or concentration, manufacturer or dispensing pharmacy, refill or lot details, storage history, and a photo of the current package.
  • Do not transfer Ozempic injection percentages or instructions to Ozempic tablets, Wegovy, a compounded vial, a research-use product, or an unlabeled injection.
  • Avoid counterfeit or no-prescription sellers, copied injection charts, unverified additives, and claims that stronger side effects prove potency, absorption, or better results.

Patient safety checklist

Questions to ask about possible Ozempic injection side effects

These points are educational and do not replace medical advice. A licensed clinician should review individual history, medications, risks, and state-specific availability before treatment.

✓

Is the product FDA-approved Ozempic injection, Ozempic tablets, another branded semaglutide product, or a patient-specific compounded prescription?

✓

Which symptoms occurred, when did they begin, how severe are they, and are they stable, improving, worsening, recurring, or limiting normal activity?

✓

Can I keep fluids and food down, how often am I urinating, and do I have repeated vomiting, diarrhea, constipation, dizziness, fainting, fever, jaundice, or severe abdominal pain?

✓

Are there vision changes, low-blood-sugar symptoms, facial or throat swelling, trouble breathing, rash, a neck mass, persistent hoarseness, or difficulty swallowing?

✓

Did symptoms follow a clinician-directed treatment change, refill, storage problem, illness, procedure, travel, diet change, alcohol use, or another medicine?

✓

Do insulin, sulfonylureas, kidney disease, diabetic retinopathy, severe stomach-emptying symptoms, gallbladder history, pregnancy plans, or an upcoming procedure change the plan?

✓

Should the current package, pharmacy label, refill or lot, storage history, inactive ingredients, or injection supplies be reviewed?

✓

Who should decide whether treatment pauses, continues, or changes, and which symptoms require same-day, urgent, or emergency care?

FAQs

Short answers for patients

What are the most common side effects of Ozempic injection?

Current Ozempic injection labeling lists nausea, vomiting, diarrhea, abdominal pain, and constipation as the most common adverse reactions. Rates vary by the studied dose group and should not be treated as a prediction for one patient or transferred to another semaglutide product.

How common is nausea with Ozempic injection?

In two placebo-controlled type 2 diabetes trials, nausea occurred in 6.1% of placebo participants, 15.8% receiving Ozempic 0.5 mg, and 20.3% receiving Ozempic 1 mg. The current table does not provide a 2 mg nausea percentage.

How long do Ozempic injection side effects last?

The current label does not provide one duration that applies to every symptom or patient. It says most nausea, vomiting, and diarrhea reports in the placebo-controlled pool occurred during dose escalation, but that is not a promise that symptoms will be brief or safe to ignore. Contact the prescriber for persistent, recurrent, worsening, severe, or intake-limiting symptoms.

Does the Ozempic injection side-effect table apply to Ozempic tablets?

No. The percentages on this page come from the current manufacturer Ozempic injection label. Current official records include a separate combined Ozempic and Rybelsus tablet label set, so route and presentation must be confirmed before applying evidence or instructions.

Do Ozempic injection rates apply to compounded semaglutide?

No. A patient-specific compounded preparation is not an FDA-approved Ozempic finished product and may differ in concentration, inactive ingredients, presentation, supplies, labeling, storage, and beyond-use date. Ozempic trial percentages do not establish its side-effect rate or quality.

Should I stop Ozempic because of side effects?

Do not skip, repeat, stop, restart, split, increase, decrease, or switch treatment based on generic online advice. Contact the responsible prescriber with the exact product and symptom pattern before the next treatment decision. Serious warning signs require prompt in-person or emergency assessment.

When are Ozempic injection side effects urgent?

Seek prompt care for severe or persistent abdominal pain, repeated vomiting, inability to keep fluids down, markedly reduced urination, fainting, confusion, jaundice, sudden vision change, trouble breathing or swallowing, facial or throat swelling, widespread hives, a neck mass with swallowing difficulty, or rapidly worsening symptoms.

Sources and related reading

Peptide12 pages use conservative educational language and authoritative sources where possible.

DailyMed: Current Novo Nordisk OZEMPIC injection prescribing information — effective June 1, 2026DailyMed: Current OZEMPIC and RYBELSUS tablet prescribing informationMedlinePlus: Semaglutide injection drug information — revised May 15, 2026MedlinePlus: Low blood sugarMedlinePlus: DehydrationFDA: Compounding and the FDA — Questions and AnswersPeptide12: OzempicPeptide12: Compounded semaglutide injectionPeptide12: Ozempic injection sitesPeptide12: Ozempic injection-site burningPeptide12: Semaglutide nauseaPeptide12: GLP-1 low blood sugarPeptide12: GLP-1 and gastroparesisPeptide12: When to message your clinicianPeptide12: How online peptide therapy works